VacZine Analytics  
MarketVIEW: Human metapneumovirus vaccines

Published: June 2015

Human metapneumovirus (hMPV) is a member of the Metapneumovirus genus in the Pneumovirinae subfamily of the Paramyxoviridae family. The virus is transmitted between humans via direct or close contact and has a seasonality of infection similar to influenza and RSV. hMPV is the second most common cause of lower respiratory tract infections after RSV in young children. Most common causes for hospitalisation with hMPV are bronchiolitis and pneumonia. Mortality from hMPV occurs in 3.46.6% of hospitalised adults.

Because of its similarity to RSV and significant global morbidity and mortality, hMPV can be considered an attractive target for a new preventative vaccine.

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of hMPV monovalent vaccines and bivalent vaccines (with RSV) across the seven major markets until 2035. The model contains value ($ m) and volume (mio doses) predictions per vaccine type /per with BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations. The product also includes an in depth review of latest hMPV epidemiological trends, treatments/guidelines and latest developments in R&D. It discusses the pros and cons of pursuing a monovalent versus bivalent approach.

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV062 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains